Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am. J. Physiol. 267 (Endocrinol. Metab. 30): E300-E305, 1994.-To investigate the effect of islet amyloid polypeptide (lAPP, amylin) exposure on insulin secretion in vivo, the plasma glucose level of conscious rats was clamped at 11.1 mmolll (hyperglycemic clamp) during the last 2 hof a 24-h infusion study. Group parameters were A, 24-h saline; Band C, 22-h saline followed by 2-h IAPP (B, 8.5 pmollmin; C, 85 pmol/min), and D, 24-h IAPP (85 pmollmin). Induced hyperglycemia increased plasma insulin concentration by 426 ± 34 pmolll in control rats (group A). This effect on plasma insulin was reduced by 31% and 53% during short-term IAPP infusion (group B, 8.5 pmollmin, 294 ± 41 pmolll; C, 85 pmollmin, 202 ± 25 pmolll; short-term effect, P < 0.0001), whereas insulin levels tended to increase after 24 h of continuous IAPP exposure (group D, 682 ± 120 pmolll; P < 0.05 vs. group A). Glucose infusion rate required to maintain constant hyperglycemia fell dose dependently during short-term but not during long-term IAPP infusion groupA, 203 ± l1;B, 154 ± 7;C, 119 ± 7; D, 212 ± 9; short-term effect, P < 0.0000. In parallel, muscle glycogen content was dose dependently reduced by short-term IAPP exposure. We conclude that IAPP inhibits glucosestimulated insulin secretion and decreases muscle glycogen storage in conscious rats in vivo.
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islet amyloid polypeptide; amylin; insulin secretion; muscle glycogen; insulin resistance ISLET AMYLOID POLYPEPTIDE (lAPP; amylin) is a 37-amino acid peptide, which has been purified from amyloid deposits in the pancreas (4, 33) , where it is synthesized in the ß-cells and cosecreted with insulin (9, 10, 12, 15, 23) .
Reduced peripheral glucose disposal and increased hepatic glucose production during euglycemic-hyperinsulinemic clamp experiments in conscious rats demonstrate induction of peripheral as well as hepatic insulin resistance by short-term infusion of IAPP in vivo (7, 8, 14) . These effects of short-term IAPP exposure on glucose homeostasis are absent after long-term IAPP exposure exceeding 22 h (8). Whereas insulin-stimulated glucose incorporation into glycogen is inhibited by IAPP in isolated muscle tissue (3, 17) , increased hepatic glucose production ensues, possibly due to a rise in supply of gluconeogenic precursors from peripheral tissue (27, 31, 35) .
Besides these effects on peripheral and hepatic glucose metabolism, lAPP may also impair insulin secretion from pancreatic ß-cells as demonstrated in isolated rat islets at an IAPP concentration of 10 j.LM (20, 24) but not at lower concentrations (2, 25) . Employing a perfused rat pancreas preparation, Sylvestre et al. (28, 29) demonstrated inhibition of insulin release by 500 nM and recently even by 75 pM IAPP. That observation was not confirmed by others, even when employing much higher IAPP concentrations (6, 20, 21) . Taken together, these conflicting results suggest inhibition by high IAPP concentration ofinsulin secretion in vitro. Conversely, a rise in arginine-induced insulin secretion has been observed in response to infusion of an IAPP-receptor antagonist in anesthetized rats (34) .
To elucidate the effects of IAPP on insulin release in vivo, freely moving rats were exposed to a strictly defined glucose stimulus by clamping at 11.1 mmolll, combined with both short (2 h)-and long-term (24 h) IAPP exposure. Plasma concentrations of insulin, as well as glycogen content of tissues, were determined. In this context, suppression by IAPP of glucose-stimulated insulin release was observed after short-but not after long-term IAPP administration.
MATERIALS AND METHODS

Animals
After approval of the study by the institutional ethics committee, male Sprague Dawley rats (Hirn: OFA/SPF; Tierforschungsinstitut, Himberg, Austria) weighing -350 g were used for the experiments. They were maintained at room temperature on a 12:12-h dark-light cycle and had free access to conventional chow diet and tap water, unless stated otherwise. After surgical implantation of catheters, rats were housed individually in Plexiglas cages (25 x 25 x 30 cm).
Surgery
Surgical and blood sampling techniques have been described in detail (13, 30) . The employed methods allow infusions and frequent blood sampling from the freely moving rat without disturbing the animal.
Vnder ether anesthesia, rats were surgically provided with a permanent silicon catheter inserted through the left carotid artery, with the tip positioned at the transition of the carotid artery and aortic arch for blood sampling and with a doublelumen silicon catheter inserted through the left jugular vein for infusion of saline/IAFP and variable glucose infusion, respectively. Catheters externalized at the animals' heads and were flushed with saline twice a week. As long as no experiment was performed, catheters were filled with heparinized (500 IV/ml) polyvinylpyrrolidone solution (Merck, Darmstadt, Germany) and closed with a cap.
At least 1 wk was given for the animals to recover from surgery before an experiment was performed. Furthermore, to avoid influence ofpsychic stress, potentially induced by attach-E300 ing the cannulas for glucose infusion and blood sampling to the catheters at the animals' heads, rats were allowed to calm down in their cages for at least 30 min before blood sampling was started.
Long-Term Infusions of Saline and IAPP
Hyperglycemic clamps were performed during the last 2 h of a 24-h saline/IAFP infusion period (0.3 ml/h). Food was withdrawn at the beginning of the infusion, and all saline/ IAFP infusates contained 2% rat plasma. Four different infusion protocols were employed. Group A (control), 24-h saline infusion; B (short-term IAPP exposure, low dose), 22-h saline infusion followed by 2 h IAPP infusion, 8.5 pmol/min (2 /-lg/h = 25.2 ± 0.9 pmol· kg-1. min-l, respectively); C (shortterm IAFP exposure, high dose), 22-h saline infusion, followed 
Hyperglycemic Clamp Tests
Hyperglycemic clamp experiments were started 22 h after food was withdrawn, and continuous infusion of saline/IAPP was initiated. Sampled blood was immediately replaced during the test using venajugularis-cannulated littermates as donors. About 0.3 ml blood was sampled at t = -20, -15, and -10 min for the determination of basal plasma glucose and plasma insulin concentration. Additionally, serum calcium was measured in blood sampled at t = -10 min. During the next JO min (Table 1) , when IAPP infusion was started in short-term IAPP-exposed rats. In long-term IAPP-infused animals, freshly prepared IAPP infusate was provided at t = 0 min to avoid reduction in biologically active IAPP in the infusion syringe during the 24-h infusion period. During the subsequent 2 h (t = 0-120 min), 75 J.LI blood were sampled every 5 min for the immediate measurement ofplasma glucose, which was used to correct the glucose infusion rate required to maintain glycemia at 11.1 mmoi/l. At t = 90, 105, and 120 min, additional blood (0.3 mD was sampled for the determination ofplasma insulin concentration. At t = 120 min, blood was also sampled for measurement of serum calcium concentrations. Thereafter, the rats were killed by intravenous thiobarbital (Sanabo, Vienna, Austria). Tissue sampies from hindlimb muscles (soleus, plantaris, red and white part of gastrocnemius), heart, and liver were quickly prepared, weighed, and immediately frozen in ethanol chilled by dry ice.
Analytical Procedures
Plasma glucose. Glucose was immediately determined by a glucose analyzer 2 (Beckman, Fullerton, CA).
Plasma insulin. Plasma was stored at -20°C, and insulin was determined in triplicate using a commercial radioimmunoassay (RIA) kit for rat insulin from Novo Nordisk (Bagsvaerd, Denmark), adapted to a plasma volume of 25 J..LI (8) . Rat insulin was used for the standard curve and inter-and intra-assay coefficients of variation were < 120/0. Serum calcium. Serum was stored at -20°C, and calcium was determined in duplicate by a dry chemistry method using 10 J..LI rat serum, an indicator dye (Arsenzano 111), and reflectance spectrophotometry (Kodak Ektachem DT 60, Eastman-Kodak, Rochester, NY). Intra-and interassay coefficients ofvariation were 1.1% and 1.7%, respectively.
Tissue glycogen. Tissues were stored at -80°C until assayed. Glycogen content was determined following homogenization of the respective tissues in distilled water by a Polytron homogenizer (PT10/35; Kinematica, Lucerne, Switzerland). Subsequently, 500 J.LI of the homogenate were incubated in duplicate with 30% KOH (wt/vol) for 30 min at room temperature. This was followed by the addition of 75 J.LI sodium sulfate (1.3 mol/I), precipitation with 1.5 ml pure ethanol, incubation for 1 h at 4°C, and centrifugation (1,350 g, 10 min). The supernatant was discarded, and sampies were evaporated to dryness under nitrogen (37°C). The remaining precipitate was dissolved in 1 ml 1 mol/l HCI and hydrolyzed at 100°C for 1 h. Sampies were neutralized with 8 mol/l NaOH, and glucose concentration was determined in duplicate, employing the hexokinase method (Human, Taunusstein, Germany). Results are given as glucosyl units per gram tissue wet weight.
Calculations and Statistics
Basal and stimulated plasma insulin as weIl as basal plasma glucose are given as the means ± SE ofthree sampies collected before and during the clamp experiment, respectively. Glucose infusion rates were calculated for the last 30 min ofthe clamp period and were space corrected (5) . Likewise, glycemia during the clamp is given for the last 30 min as the mean concentration measured in plasma sampIes obtained every 5 min.
Data were analyzed by analysis of variance employing SAS programs (SAS Instruments, Cary, NC), which suggested normal data distribution. P values were derived 1) by Dunnett test for comparison of (see Fig. 1 
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linear-contrast calculation. The latter method evaluates a linear dose-dependent trend for data obtained from short-term IAPP-infused groups A, B, and C. Data are given as means ± SE, P < 0.05 were considered significant and referred to as P (Dunnett test) or P* (linear-contrast calculation).
RESULTS
Body weight, basal glycemia, and basal insulinemia were not different in the various experimental groups, and target hyperglycemia of 11.1 mmol/l was weIl maintained duringthe last 30 min ofthe clamp (Table 1) .
Insulin secretion was markedly impaired by shortterm IAPP exposure (group B, 8.5 pmol/min; group C, 85 pmol/min), as demonstrated by lower plasma insulin levels duringthe last 30 min ofthe hyperglycemic clamp period (P* < 0.005; Table 1 ). Incremental insulinemia above basal during the hyperglycemic clamp was 426 ± 34 pmol/l in control animals (group A) but dose dependently reduced by 31% to 294 ± 41 pmol/l (group B) and by 53% to 202 ± 25 pmol/l (group C) in rats infused short term with 8.5 pmol/min and 85 pmol/min IAPP, respectively (P* < 0.0001, Fig. 1 ). IAPP action on insulin secretion faded when infused for 24 h (Table 1, Fig.  1 ). Increased mean incremental insulinemia in longterm IAPP-exposed rats (group D, 682 ± 120 pmol/l, P < 0.05 vs. group A) was mainly due to two animals clearly deviating from the range seen in animals of the control group (Fig. 1) .
Glucose infusion rate required to maintain hyperglycemia at 11.1 mmol/l was significantly lower during short-term IAPP infusion than in control experiments, which required a glucose infusion rate of 203 ± 11 J.1mol· kg-1 . min-1. This effect was dose dependent, displaying a decrease by 24% in rats infused with 8.5 pmol/min IAPP (154 ± 7 J.1mol·kg-1 ·min-1 ) and by 41% in animals receiving 85 pmol/min IAPP (119 ± 7 J.Lmol·kg-1 ·min-1 ; P* < 0.0001; Fig. 1 ). When IAPP was infused for 24 h at a rate of 85 pmol/min, glucose infusion rate did not differ from that in the control group (groupA: 212 ± 9 J.1mol·kg-1 ·min-1 ).
Serum calcemia was decreased by short-term highdose IAPP exposure (P < 0.01) at t = 120 min of the clamp experiment but not by its low-dose or long-term infusion (Table 2) . No differences between groups were found in glycogen content of liver and heart muscle (Fig. 2) . The higher mean value for liver glycogen in long-term IAPP-infused rats was due to a single outlier exhibiting a glycogen eontent of 59.4 J.1mol glucosyl units/g liver. Short-term IAPP exposure (groups Band C), however, markedly decreased mean glycogen content of various hindlimb muscles (P * < 0.05 for white gastrocnemius; P* < 0.0001 red gastrocnemius, soleus, and plantaris; Fig. 2 ). When expressed as percentage of control values, the proportionate decrease in muscle glycogen content was more pronounced than that of the total amount of glucose infused duringthe experiments (Table 3) . Again, the effects of short-term IAPP infusion totally vanished during its long-term administration. 
DISCUSSION
This study demonstrates that short-term IAPP infusion, at rates known to affect insulin sensitivity (7, 8, 14) , markedly inhibits glucose-stimulated insulin seeretion in vivo during a 11.1 mmol/l hyperglyeemie clamp (Fig. 1, Table 1 ). Such suppression by IAPP of insulin secretion has previously been described during intravenous glucose tolerance tests in humans and cats (1, 11) . However, due to IAPP-induced glucose intolerance (8, 11) , these experimental conditions did not provide for a comparable glycemic stimulus of insulin secretion. The difficulty in evaluating IAPP action may, however, be overcome by a hyperglycemic clamp, which allows us to compare IAPP action on insulin secretion at a strictly defined glucose concentration. Thus the mean glucosestimulated increase in plasma insulinemia was found to Values are means ± SE. Clamp tests were performed during last 2 h of 24-h saline/IAPP infusion. Group parameters are described in Table 1 . *For calcium after clamp, P* < 0.0001, linear-contrast calculation for short-term effect; P < 0.01, Dunnett test, group A vs.
C.
be markedly decreased by 31 and 53% when lAPP was short-term infused at rates of 8.5 and 85 pmol/min, respectively. . Estimating induced plasma lAPP concentration from results reported by others in short-term IAPP-infused rats (7, 14) , plasma levels of 100-200 pmolll would prevail for low-dose (8.5 pmol/min, group B) and of > 2,000-3,000 pmolll for high-dose (85 pmol/min,group C) lAPP-infused rats (Fig. 3) . Such estimation ofplasma levels remains problematic, since RIA systems for the determination of human or rat IAPP are not yet sufficiently standardized (16) . Only the high infusion rate increased adenosine 3' ,5' -cyclic monophosphate (cAMP) levels in plasma and soleus muscle tissue (data not shown). Absence of changes of cAMP concentrations in the low-dose group indicates that plasma IAPP concentration was at least low enough not to exert effects via receptors for calcitonin gene-related peptide. It also has to be kept in mind that endogenous IAPP, like insulin, is released from ß-cells and, following its release, will display considerably higher local concentrations within the islets of Langerhans than in plasma. Such higher local IAPP concentration may even permit for paracrine intraislet inhibition of insulin release. Such an hypothesis of local IAPP action is corroborated in part by inhibition of insulin release from isolated pancreas (28, 29) , isolated islets (20, 24) , and even isolated ß-cells (32) , although no such effect was observed by others (2, 6, 21, 25) .
Speculating on a physiological potential of IAPP action in vivo, it is of note that the estimated induced plasma lAPP levels of this study are markedly lower than the 10 jJ..molll reported to inhibit insulin secretion from isolated islets in vitro (20, 24) . Such difference may stern from accumulation of IAPP secreted from ß-cells of isolated islets in vitro, causing extremely high local concentrations, whose action can hardly be overcome by added lAPP. Comparable local accumulation is, however, unlikely to occur in vivo, since the peptide will be subject to permanent washout by circulating blood. This assumption is in line with a study employing the perfused rat pancreas, demonstrating inhibition of insulin release by 75 pM IAPP (28), although no inhibitory effect was found at much higher IAPP concentrations by others (6, 20, 21) .
The mean reduction in glucose infusion rates required to maintain constant hyperglycemia was 24 and 41% in rats short-term infused with 8.5 and 85 pmol/min IAPP, respectively (Fig. 1) , and corresponded to similar decreases in plasma insulin of 26 and 38% (Table 1) . Hence, reduction in circulating insulin concentration seems to be a major cause of decreased glucose uptake during these experiments. IAPP-induced insulin resistance demonstrated during euglycemic hyperinsulinemic clamp tests (7, 8, 14) may therefore reflect only in part lAPP's intrinsic action on carbohydrate metabolism.
Reduction by IAPP in overall glucose disposal seems to be corroborated by parallel impairment in glycogen storage (Fig. 2) . The proportionately greater fall in muscle glycogen storage than in amount of infused glucose, together with unchanged liver glycogen content, supports the contention that IAPP is an insulinantagonistic regulator of the Cori cycle, shifting glycogen storage from muscle to liver (26) . Comparing the proportional decrease in glycogen content between the various muscles investigated in response to low-dose lAPP infusion (8.5 pmol/min), lAPP sensitivity seems contral group A: *P < 0.05, ** P < 0.01.
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Values are means ± SE. Clamp test was performed during last 2 h of 24-h saline/lAPP infusion. Relative changes are expressed as % control group A. Group parameters are described in Table 1 . *For total glucose infused, P* < 0.0001, linear-contrast calculation for shortterm effect; P < 0.01, Dunnett test, group A vs. B, A vs. C. to relate to reduction in glycogen storage of fast-twitch vs. slow-twitch muscle fibers (white gastrocnemius, mainly fast-twitch fibers; 43% of control'> plantaris, mixed fibers; 56% > soleus, and red gastrocnemius, mainly slow-twitch fibers; 79 and 67%, respectively).
Reduction by IAPP in glycogen content ofwhite gastrocnemius muscle in response to 8.5 pmol IAPPImin obviously reflects maximal sensitivity to IAPP, since no further change was induced during infusion of 85 pmol/min. Such higher sensitivity of fast-vs. slowtwitch muscle fibers has also been demonstrated in vitro for calcitonin gene-related peptide, which shares '" 50% homology with lAPP (19) . Fading ofIAPP action on tissue glucose uptake following its long-term (> 22 h) infusion has previously been described in an euglycemic hyperinsulinemic clamp study (8) . In the present study, IAPP's inhibitory effect on insulin secretion is also absent after a high-dose infusion period > 22 h (Fig. 1) . The results indicate tissue desensitization to IAPP in response to its long-term infusion but n1ay also reflect a reactive increase in lAPP clearance rate. Potential differences between experimentallong-term IAPP exposure and chronic elevations in endogenous IAPP plasma levels that may occur together with hyperinsulinemia in vivo include lAPP exposure pattern (continuous vs. oscillatory), period (24 h vs. months or even years), and actual plasma levels. Hence, although the present study principally demonstrates fading of IAPP action after 22 h, further investigations are necessary to elucidate the physiological relevance and underlying mechanisms of that phenomenon. In this context, excessively increased plasma insulin levels in some long-term IAPP-infused rats deviating markedly from the range of control animals may hint at insulin resistance caused by prolonged IAPP exposure, as suggested by others (18) . However, results from two outliers do not allow final conclusions.
The decrease in serum calcemia seen during shortterm IAPP exposure returned to controllevels following long-term lAPP infusion (Table2), which is at variance to data observed during euglycemic clamping in a different rat strain (8) . As the infusate was freshly prepared for the last 2 h of the 24-h infusion period, loss of lAPP bioactivity can be excluded as the cause of fading lAPP action. Rather, mechanisms like downregulation ofreceptors on target tissues, exhaustion of a substratemediating IAPP action, or receptor blockade by fragments of degraded peptide (22) may add to this phenomenon.
In summary, short-term IAPP infusion is demonstrated to markedly inhibit insulin secretion and to reduce muscular glycogen storage dose dependently in rats during constant hyperglycemia (11.1 mmoll1). These effects fade during long-term IAPP exposure. IAPPĩ nduced inhibition ofinsulin release may be ofphysiological importance, if higher intraislet than plasma concentration of endogenous IAPPelicits paracrine action. 
